G1 Therapeutics Inc (NASDAQ:GTHX) Short Interest Update

G1 Therapeutics Inc (NASDAQ:GTHX) saw a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 3,673,600 shares, a growth of 8.2% from the May 15th total of 3,395,700 shares. Currently, 14.2% of the shares of the stock are short sold. Based on an average daily volume of 437,500 shares, the short-interest ratio is currently 8.4 days.

Several equities research analysts recently weighed in on GTHX shares. BidaskClub cut shares of Walgreens Boots Alliance from a “sell” rating to a “strong sell” rating in a research report on Monday, June 24th. Cowen restated a “buy” rating on shares of G1 Therapeutics in a research report on Tuesday, June 18th. Finally, Zacks Investment Research lowered shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 16th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $60.43.

Shares of GTHX traded up $0.40 during trading hours on Friday, reaching $25.70. 362,086 shares of the company traded hands, compared to its average volume of 518,140. The stock has a market capitalization of $962.90 million, a price-to-earnings ratio of -10.04 and a beta of 2.68. G1 Therapeutics has a 12-month low of $13.87 and a 12-month high of $69.57. The stock has a fifty day moving average of $24.70.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.64) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.05. On average, equities analysts expect that G1 Therapeutics will post -2.89 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc lifted its stake in G1 Therapeutics by 20.0% in the fourth quarter. Legal & General Group Plc now owns 4,060 shares of the company’s stock worth $78,000 after acquiring an additional 676 shares during the period. American International Group Inc. raised its holdings in G1 Therapeutics by 8.5% in the fourth quarter. American International Group Inc. now owns 15,004 shares of the company’s stock worth $287,000 after purchasing an additional 1,177 shares in the last quarter. Rhumbline Advisers raised its holdings in G1 Therapeutics by 5.6% in the first quarter. Rhumbline Advisers now owns 29,815 shares of the company’s stock worth $495,000 after purchasing an additional 1,569 shares in the last quarter. Two Sigma Advisers LP increased its holdings in shares of G1 Therapeutics by 7.0% during the fourth quarter. Two Sigma Advisers LP now owns 28,900 shares of the company’s stock valued at $553,000 after acquiring an additional 1,900 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale increased its holdings in shares of G1 Therapeutics by 22.3% during the first quarter. DekaBank Deutsche Girozentrale now owns 11,500 shares of the company’s stock valued at $691,000 after acquiring an additional 2,100 shares in the last quarter. 73.35% of the stock is owned by institutional investors.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Further Reading: What is a recession?

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.